A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 20 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 20 Jul 2017 Status changed from completed to active, no longer recruiting.
- 10 May 2017 Status changed from active, no longer recruiting to completed.